ArticleNPJ vaccines2024

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine.

David G Alleva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.